

6. Packaging:

- A) KIPRES Tablet 10: 100 tablets, 140 tablets, and 420 tablets
- B) KIPRES Chewable Tablet 5: 100 tablets

Kyorin will seek to penetrate the respiratory market by focusing its KIPRES marketing on the respiratory specialists with whom it has developed strong relationships. This marketing push will ultimately strengthen Kyorin's "base of business" in the respiratory area.

KIPRES is a joint-development/joint-sales product with Banyu Pharmaceutical Co. and is licensed from Merck & Co., Inc. Kyorin was given the rights to KIPRES as a result of a cross-licensing agreement with Merck, in which Merck received the diabetes treatment medicine, KRP-297.

For more information please contact:

Kyorin Pharmaceutical Co., Ltd.

Marketing Planning Department

5, Kanda Surugadai 2-Chome

Chiyoda-Ku, Tokyo 101-8311 JAPAN

Tel: 03-3293-3414

Fax: 03-3293-3450

E-mail: kyorinpm@mb.infoweb.ne.jp

Homepage: <http://www.kyorin-pharm.co.jp/>